NCT04875286

Brief Summary

This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
8mo left

Started Feb 2021

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Feb 2021Feb 2027

Study Start

First participant enrolled

February 3, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 22, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 6, 2021

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 2, 2027

Last Updated

March 5, 2026

Status Verified

March 1, 2026

Enrollment Period

6 years

First QC Date

April 22, 2021

Last Update Submit

March 3, 2026

Conditions

Cancer-Associated PainHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief

    Will be calculated and reported along with a 95% confidence interval.

    through study completion, an average of 1 year

Secondary Outcomes (8)

  • Perception of cancer-related symptom relief

    through study completion, an average of 1 year

  • Patient perception of THC-marijuana and/or CBD

    through study completion, an average of 1 year

  • To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD

    through study completion, an average of 1 year

  • To evaluate patient reported concerns while using THC-marijuana and/or CBD

    through study completion, an average of 1 year

  • Patient attitude of dosing, forms and use of THC-marijuana and/or CBD

    through study completion, an average of 1 year

  • +3 more secondary outcomes

Study Arms (1)

Observational (medical record review, questionnaires))

Patients' medical records are reviewed and then complete questionnaires over 27 minutes.

Other: Electronic Health Record ReviewOther: Questionnaire Administration

Interventions

Electronic Health Record ReviewOTHER

Medical records reviewed

Observational (medical record review, questionnaires))
Questionnaire AdministrationOTHER

Complete questionnaires

Observational (medical record review, questionnaires))

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona)

You may qualify if:

  • Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona)
  • Patients must be primary residents of Texas or Arizona
  • Patients able to speak and read English
  • Patients are 18 years old and above
  • Patients should have a cancer diagnosis, cancer-associated pain, and taking strong opioids (morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, methadone, fentanyl)
  • Patients who have used in the past 3 months or are using alternative botanical pain management while under prescription opioids

You may not qualify if:

  • Patients who are not able to speak or read English
  • Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process
  • Patients who have not used medical marijuana and/or CBD products
  • Patients who do not have cancer
  • Patients who do not have cancer-associated pain
  • Patients who are not taking opioids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States

Location

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Cancer PainHematologic Neoplasms

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Kimberson C Tanco

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 22, 2021

First Posted

May 6, 2021

Study Start

February 3, 2021

Primary Completion (Estimated)

February 2, 2027

Study Completion (Estimated)

February 2, 2027

Last Updated

March 5, 2026

Record last verified: 2026-03

Locations

US(2)